Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
  • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/24—Metalloendopeptidases (3.4.24)
  • C12Y304/2404—Serralysin (3.4.24.40)

Definitions

• the present invention relates to a method of treating infectious disease, wherein the treatment comprises administration of Serratiopeptidase, Mannose or isomers, salts, other derivatives thereof, and one or more antiinfection agents, in same or different compositions to humans or animals.
• the present invention relates to a pharmaceutical composition comprising Serratiopeptidase and Mannose or isomers, salts, other derivatives thereof.
• the present invention relates to a pharmaceutical composition comprising Serratiopeptidase, Mannose or isomers, salts, other derivatives thereof, and one or more antiinfection agents.
• the pathogen In Infection, the pathogen first invades the host organs and over a period these free floating pathogen attached to the surface of the cell tissue with the help of fimbriae. These pathogen then grows as a colony and secrets extracellular polymers that provides a structural and protective matrix, called Biofilm. This biofilm provides protection to pathogen against an anti-infective agents.
• Current therapy in recurrent Infection involves an anti -infective therapy only. The anti- infective agent only eradicates free floating pathogens but the pathogens under the biofilm are protected against the anti-infective agents. These protected pathogens regrow after sometimes and are the source of recurrent infections.
• a solution to current recurrent infection treatment is to dissolve biofilm and block the fimbriae of pathogen so it does not attached to cell surface. This helps to prevent colonization of pathogen and prevents the new biofilm formation.
• the present invention provides solution to method of treating infectious disease, wherein treatment comprises administration of Serratiopeptidase, Mannose or its derivatives and one or more antiinfection agents in same or different compositions to humans or animals.
• treatment comprises administration of Serratiopeptidase, Mannose or its derivatives and one or more antiinfection agents in same or different compositions to humans or animals.
• This combination keeps the pathogen in free floating state without biofilm or without pathogen attachment and provides improved anti-infection effect on free floating pathogen which helps in eradicating the infection.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising Serratiopeptidase and Mannose or isomers, salts, other derivatives thereof.
• the pharmaceutical composition optionally may further comprise one or more antiinfection agents.
• the present invention relates to a method of treating infectious disease, wherein the treatment comprises administration of Serratiopeptidase, Mannose or isomers, salts, other derivatives thereof, and one or more antiinfection agents in same or different compositions to humans or animals.
• Fig 1 describes comparative bacterial growth suppression along with the combination as per present invention.
• the present invention relates to a pharmaceutical composition and a method of treatment using Serratiopeptidase, Mannose or isomers, salts, other derivatives thereof, and optionally one or more antiinfection agents.
• the active ingredient as per present invention are used in therapeutically effective amount.
• anti-infective agents or “antiinfection agents” are used interchangeably.
• “Therapeutically effective amount” or “effective amount” refers to the amount of a pharmaceutically active agent when administered to a patient, is sufficient to affect such treatment for the disease.
• the therapeutically effective amount will vary depending on the disease and its severity, and the age, weight, and other conditions of the patient to be treated.
• compositions refers to any composition for administration to human or animal includes but are not limited to immediate release, delayed release, extended release and pulsed-release.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. a therapeutically effective amount of Serratiopeptidase, and b. a therapeutically effective amount of Mannose or isomers, salts, other derivatives thereof.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. a therapeutically effective amount of Serratiopeptidase, and b. a therapeutically effective amount of D-Mannose.
• the present invention relates to an oral pharmaceutical composition
• an oral pharmaceutical composition comprising a. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and b. D-Mannose in an amount between 0.1 mg and 1000 mg.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. a therapeutically effective amount of Serratiopeptidase, b. a therapeutically effective amount of Mannose or isomers, salts, other derivatives thereof, and c. a therapeutically effective amount of one or more antiinfection agents.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. a therapeutically effective amount of Serratiopeptidase, b. a therapeutically effective amount of D-Mannose, and c. a therapeutically effective amount of an Antibiotic.
• the present invention relates to an oral pharmaceutical composition
• an oral pharmaceutical composition comprising a. Serratiopeptidase in an amount between 0.1 mg and 200 mg, b. D-Mannose in an amount between 0.1 mg and 1000 mg, and c. therapeutically effective amount of an Antibiotic.
• the present invention relates to a method of treating infectious disease, wherein said treatment comprises administration of a. a therapeutically effective amount of Serratiopeptidase, b. a therapeutically effective amount of Mannose or isomers, salts, other derivatives thereof, and c. a therapeutically effective amount of one or more antiinfection agents, wherein said administration is in same or different compositions and said treatment is administered to humans or animals.
• the present invention relates to a method of treating infectious disease, wherein said treatment comprises administration of a. a therapeutically effective amount of Serratiopeptidase, b. a therapeutically effective amount of D - Mannose, and c. a therapeutically effective amount of an Antibiotic, wherein said administration is in same or different compositions and said treatment is administered to humans or animals.
• the present invention relates to a method of treating infectious disease, wherein said treatment comprises administration of a. Serratiopeptidase in an amount between 0.1 mg and 200 mg, b. D-Mannose in an amount between 0.1 mg and 1000 mg, and c. therapeutically effective amount of an Antibiotic, wherein said administration is in same or different compositions and said treatment is administered to humans or animals.
• a pharmaceutical composition as per present invention includes immediate release, delayed release, extended release or combination thereof.
• a pharmaceutical composition as per present invention includes for oral, intravenous, topical, inhalation or other routes of administration.
• a pharmaceutical composition as per present invention includes solid, liquid, semisolid, aerosol or other dosage forms.
• said pharmaceutical composition or treatment is for urinary tract infection or respiratory tract infection or soft tissue infection or bone infection or skin infection or blood/plasma infection or GI track infection.
• a pharmaceutical composition as per present invention comprises one or more antibiotics selected from Aminoglycosides, Carbapenems, Glycopeptides, Quinolones, Penicillins, Fluoroquinolones, Cephalosporins, Sulfonamides, Macrolides, Nitrofurantoin, Metronidazole. Rifamycin, Tetracyclines, Lincomycin, telithromycin and/or other antibiotics.
• invention relates to the treatment of Recurrent Urinary Tract Infection with administration of a. Nitrofurantoin in an amount between 25 mg and 100 mg, b. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and c. D-Mannose in an amount between 0.1 mg and 1000 mg.
• invention relates to the treatment of Recurrent Urinary Tract Infection with administration of a. Ciprofloxacin/Levofloxacin in an amount between 250 mg and 1000 mg, b. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and c. D-Mannose in an amount between 0.1 mg and 1000 mg.
• invention relates to the treatment of Respiratory Tract Infection with administration of a. Azithromycin/Levofloxacin in an amount between 0.1 mg and 1000 mg, b. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and c. D-Mannose in an amount between 0.1 mg and 1000 mg.
• invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. Nitrofurantoin in an amount between 25 mg and 100 mg, b. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and c. D-Mannose in an amount between 0.1 mg and 1000 mg.
• invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. Ciprofloxacin/Levofloxacin in an amount between 250 mg and 1000 mg, b. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and c. D-Mannose in an amount between 0.1 mg and 1000 mg.
• invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a. Azithromycin/Levofloxacin in an amount between 0.1 mg and 1000 mg, b. Serratiopeptidase in an amount between 0.1 mg and 200 mg, and c. D-Mannose in an amount between 0.1 mg and 1000 mg.
• Serratiopeptidase is a proteolytic enzyme prescribed in surgery, orthopaedics, dentistry, otorhinolaryngology and gynaecology for its anti-inflammatory, anti-edemic and analgesic effects. It is produced by non-pathogenic enterobacterium Serratia. This microorganism was originally isolated in the late 1960s from silkworm. Serratiopeptase may be produced by purification from culture of Serratia E-15 bacteria.
• Serratiopeptidase is administered in the therapeutically effective amount of between 0.1 mg and 200 mg, preferably between 10 mg and 120 mg. In a preferred embodiment, Serratiopeptidase may be used in the amount of 0. lmg or more for lung delivery or aerosols. In one or more embodiments of the present invention, Serratiopeptidase may be administered as enteric coated dosage form. Enteric coating consists of pH sensitive polymers which remains intact in the gastric acidic pH (1.5-3.5) and solubilises in the alkaline pH (6.5-7.6) of the small intestines.
• Mannose occurs in microbes, plants and animals. Free mannose is found in small amounts in many fruits and in mammalian plasma. Mannose commonly exists as two different-sized rings, the pyranose (six-membered) form and the furanose (five-membered) form. Each ring closure can have either an alpha or beta configuration at the anomeric position. The chemical rapidly undergoes isomerization among these four forms. D-Mannose can be as a-D-Mannofuranose / a-D-Mannopyranose / b-D-Mannopyranose b-D-Mannopyranose
• the present invention involves use of preferably D-Mannose.
• D-Mannose is an epimer of glucose at the C-2 position and exists in nature as a component of mannan. It is a sugar monomer of the aldohexose series of carbohydrates.
• D-Mannose may be used in the amount of between 0.1 mg and 1000 mg. In a preferred embodiment, D-Mannose can be used in the amount of 0.1 mg or more for lung delivery or aerosols. In a preferred embodiment, D-Mannose can be used in the amount of 10 mg to 1000 mg.
• Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi or parasites. Microorganisms that cause disease are called pathogens. Pathogens cause disease either by disrupting the bodies normal processes and/or stimulating the immune system to produce a defensive response, resulting in high fever, inflammation and other symptoms. Infectious diseases are transmit in one or more of following
• insects or other animals By insects or other animals,
• Anti-infective agents are chemicals which are used to treat infection. Use of anti-infective agents depends on the type of organism targeted. These anti-infective agents include antibacterial (antibiotics), antiviral, antifungal and antiparasitic agents and administered orally, intravenously or by other suitable routes depending on the severity, location and the type of infection.
• Bacteria are single-celled microorganisms and comes in many shapes including ball-, rod- and spiral-shaped. Infectious bacteria can grow, divide and spread in the body, leading to infectious disease. Many infectious bacteria secretes toxins which increases severity of some diseases.
• Antibiotics are medications that kills or inhibits down the growth of bacteria and are widely used in the treatment and prevention of such infections.
• antibiotics are Aminoglycosides, Penicillins, Cephalosporins, Carbapenems, Glycopeptides, Quinolones, Fluoroquinolones, Sulfonamides, Macrolides, Nitrofurantoin, Metronidazole, Rifamycin, Tetracyclines, Lincomycin, Telithromycin and/or other antibiotics.
• Viruses are tiny capsules that contain genetic material and replicate only in the living cells of other organisms. They invade cells, multiplies and damage the cells. They can infect human, animals, plants, bacteria and other forms of living bodies.
• Antiviral drugs are a class of medication used specifically for treating viral infections. Most antivirals are used for specific viral infections but broad spectrum antivirals are effective against a wide range of viruses. The different types of antivirals are Protease inhibitor, Integrase inhibitor, Reverse transcriptase inhibitor, Neuroamidase inhibitors, Guanosine analogs and and/or other antiviral.
• the pharmaceutical compositions are the different type of medicinal preparation designed for the administration of targeted one or more drugs.
• the pharmaceutical compositions as per present invention includes immediate release, delayed release, extended release and pulsed-release.
• the pharmaceutical compositions can be prepared using uniform mixture of two or more drugs.
• pharmaceutical composition can be prepared with one or more drugs in separate compartment within a single dosage form.
• the pharmaceutical compositions as per present invention can be administered by oral, topical, inhalation, intravenous or other routes of drug administration.
• the pharmaceutical compositions as per present invention can be solid, liquid, semisolid, aerosol or any other dosage form.
• the pharmaceutical compositions as per present invention can be prepared as one or more drug in modified release and other drugs as immediate release in single dosage form.
• the oral pharmaceutical dosage form are tablets, capsules, solutions, emulsions, suspensions, syrups, elixirs, aerosol, powders and granules for reconstitution, lozenges, dispersible powders and granules, medicated gums, chewing tablets, effervescent tablets, multi-particulate dosage forms and the likes.
• the multicompartment dosage form are bilayer tablets, capsule-in-capsule, tablet-in capsule and any other dosage form.
• the pharmaceutical compositions can be formulated by any techniques known to or appreciated by a person skilled in the art
• the oral pharmaceutical composition further includes optionally any one or a combination of one or more pharmaceutically acceptable excipients, such as but not limited to carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants and solubility enhancers.
• pharmaceutically acceptable excipients such as but not limited to carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants and solubility enhancers.
• a nutrient media was prepared with a plastic thread suspended in it.
• the nutrient media was inoculated with bacteria and was kept overnight leading to the formation of biofilm.
• plastic thread was moved to new nutrient media with either D-Mannose or Serrapeptidase or both D-Mannose and Serrapeptidase or Blank (No Addition) and bacterial was allowed grows for 6 to 7 hours. After 6-7 hours, plastic thread was added to new nutrient media and then antibiotic was added.
• the thin plastic thread was transferred from old test tube to new test tube on second day 11AM. All 5 test tubes were kept at 30 °C - 35 °C for 7 hours.
• test tube 1 On third day 11 AM, add 1ml of Solution A dl1 (Diluted Antibiotic (nitrofurantoin) solution) to test tube 1, test tube 2, test tube 3 and test tube 4. All 5 test tubes were kept at 30 °C - 35 °C for 7 hours.
• Solution A dl1 Diluted Antibiotic (nitrofurantoin) solution
• Test tube 1 With solution F (D-Mannose) and A dl1 (Diluted Antibiotic): 8.6 b.
• Test tube 2 With Solution P (Serrapeptidase) and A dl1 (Diluted Antibiotic): 8.3 c.
• Test tube 3 With Solution F (D-Mannose), P (serrapeptidase) and A dl1 (Diluted Antibiotic): 9.0 d.
• Test tube 4 With A dl1 (Diluted Antibiotic): 8.4 e.
• Test tube 5 Blank : 8.3 [0053] Procedure 2:
• the thick plastic thread was transferred from old test tube to new test tube on fifth day at 11 AM. All 5 test tube were kept at 30° - 35° C for 7 hours.
• test tube 3 On fifth day 6PM, another five (5) sterile test tubes were added with 50ml of Sterile Soybean Casein Digest Medium. Then 1ml of Solution A (Antibiotic (nitrofurantoin) solution) was added to test tube 1, test tube 2, test tube 3 and test tube 4. The thick plastic thread was transferred from old test tube to new test tube on fifth day at 6PM. All Five (5) test tube were kept at 30° - 35° C for overnight (17 hours).
• Solution A Antibiotic (nitrofurantoin) solution
• Test tube 1 With solution F (D-Mannose) and A (Antibiotic): 5.7 b.
• Test tube 2 With Solution P (Serrapeptidase) and A (Antibiotic): 6.0 c.
• Test tube 3 With Solution F (D-Mannose) ,P (serrapeptidase) and A (Antibiotic): 10.7 d.
• Test tube 4 With A (Antibiotic): 6.9 e.
• Test tube 5 Blank : 8.8

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• General Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Dermatology (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=77463237

Family Applications (1)

Country Status (9)

Citations (2)

Family Cites Families (6)

• 2021
  • 2021-03-02 CN CN202180027170.7A patent/CN115361953A/zh active Pending
  • 2021-03-02 BR BR112022016132A patent/BR112022016132A2/pt unknown
  • 2021-03-02 AU AU2021229482A patent/AU2021229482A1/en active Pending
  • 2021-03-02 JP JP2022552748A patent/JP7758906B2/ja active Active
  • 2021-03-02 CA CA3164767A patent/CA3164767A1/en active Pending
  • 2021-03-02 US US17/189,767 patent/US20210268075A1/en active Pending
  • 2021-03-02 EP EP21765204.9A patent/EP4114407A4/en active Pending
  • 2021-03-02 WO PCT/US2021/020411 patent/WO2021178371A1/en not_active Ceased
• 2022
  • 2022-08-29 ZA ZA2022/09623A patent/ZA202209623B/en unknown

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events